Posts tagged as: Cellceutix news back to homepage
 |
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
 |
FDA to Expedite the Drug Approval Process for Breakthroughs(0) An article released yesterday by Reuters titled, “U.S. may speed approval of ‘breakthrough’ drugs” could prove extremely valuable for biotechs of all sizes. According to the article,
Smaller companies like Cellceutix Corporation (OTCBB: CTIX) will be closely watching for the proposal to become law as it could expedite the development of its anti-cancer drug Kevetrin™, a completely new class of chemistry that lab studies showed to reactivate p53, a critical regulator of the cell cycle that is damaged or malfunctioning in the vast majority of cancers. Given its uniqueness and promising pre-clinical data, the drug certainly has the potential to qualify as a “breakthrough.” Clinical trials should be starting in the next couple months at Harvard’s Dana-Farber Cancer Institute, which is a milestone that investors have been waiting for as Cellceutix looks to leap to the forefront of cancer researchers. Cellceutix (CTIX) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer. |
 |
Jim Boeheim and Cellceutix Team to Fight Cancer(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers),is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Read More |
 |
Cellceutix CEO Interview on TheStreetBeat Part II(0) Below is Part II of the CEO Interview from TheStreetBeat.com with Cellceutix CEO Leo Ehrlich, including the video and the text script. Read More |
|
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com(1) The latest edition of TheStreetBeat.com’s CEO Interview series features Cellceutix Chief Executive Officer Leo Ehrlich. The interview is being released in two parts, with Part One of the interview released this afternoon and Part Two slated Read More |
|
Cellceutix to Meet with FDA on New Psoriasis Drug(0) This one day might be the story called “The Little Biotech That Could”. Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism). The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More |
|
Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting(0) Company on Schedule for Filing Amended IND - Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is pleased to provide shareholders an update on developments with its novel anti-cancer compound Kevetrin™. Read More |
 |
Cellceutix Pens Agreement for Cancer Drug with Beth Israel Deaconess(0) Cellceutix Corporation (OTCBB:CTIX) continues to align itself with the biggest names in oncology research in the world. This truly sets the company apart from most of it developmental peers, regardless of exchange-listing or size. The company has released news recently about FDA document submissions seeking guidance on 505(b)(2) clearance for its psoriasis drug (which has provider stellar pre-clinical data) in addition to the clinical trials for its flagship cancer drug, Kevetrin™, which should be starting at Dana-Farber in the coming months. Read More |
350.png&w=160&h=120&zc=1&q=100) |
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0) Company Gets Started on Next Drug in Their Pipeline Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More |
|
Cellceutix Featured on Front Page of Boston Business Journal(0) Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that it was featured Friday, January 20th on the front page of the Boston Business Journal print edition. Owned by American City Business Journals, the Boston Business Journal is available in both print and online versions and reaches hundreds of thousands of subscribers each month. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
